Cellular based treatment modalities for unresectable hepatocellular carcinoma

Area of Science:

• Hepatology and Oncology
• Immunotherapy research
• Translational cancer medicine

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited treatment options for advanced stages.
• Current systemic therapies, including sorafenib and immune checkpoint inhibitors, offer survival benefits but necessitate further innovation.
• There is a critical need for novel treatments to improve outcomes and reduce recurrence in HCC.

Purpose of the Study:

• To review current systemic treatments for HCC.
• To present evidence for emerging immunotherapeutic strategies in HCC.
• To compile ongoing clinical trials and discuss challenges in cellular therapy for HCC.

Main Methods:

• Literature review of approved systemic therapies for HCC.
• Analysis of preclinical and clinical data on HCC immunotherapies.
• Compilation of ongoing clinical trials for CAR-T cells, TCR engineered T cells, cancer vaccines, and oncolytic viruses.

Main Results:

• Approved systemic therapies include molecular-targeting agents and immune checkpoint inhibitors.
• Adoptive cell therapies (CAR-T, TCR, NK cells, TILs) demonstrate potential in hematologic and solid tumors.
• Numerous clinical trials are investigating novel cellular therapies and other immunomodulatory approaches for HCC.

Conclusions:

• Immunotherapy represents a significant advancement in HCC treatment, offering new hope for patients.
• Adoptive cell therapies and other novel immunomodulatory strategies hold promise for revolutionizing unresectable HCC treatment.
• Overcoming challenges in cellular therapy is crucial for realizing the full potential of these innovative treatments.